In our study, we explore the effect of CXCL10 on persistent tumors, demonstrate that tumor and immune cells undergo crosstalk during EGFR-TKI treatment, and suggest that this crosstalk could impact the efficacy of EGFR-TKI treatment. The gene discussed is CXCL10; the disease is neoplasm.